Influence of XOI, Febuxostat, on Vascular Function in Patients with Hyperuricemia and Cardiovascular Risk Factors

Trial Profile

Influence of XOI, Febuxostat, on Vascular Function in Patients with Hyperuricemia and Cardiovascular Risk Factors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2016

At a glance

  • Drugs Febuxostat (Primary) ; Allopurinol
  • Indications Aortic dissection; Cerebrovascular disorders; Diabetes mellitus; Dyslipidaemias; Hypertension; Hyperuricaemia; Ischaemic heart disorders; Metabolic syndrome; Renal impairment
  • Focus Pharmacodynamics
  • Acronyms J-XOI study
  • Most Recent Events

    • 03 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top